

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				<div style="text-align: right; font-size: small;">Complete if Known</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Application Number</td> <td>10/509,009</td> </tr> <tr> <td>Filing Date</td> <td>May 3, 2005</td> </tr> <tr> <td>First Named Inventor</td> <td>Chiquet-Ehrismann et al.</td> </tr> <tr> <td>Art Unit</td> <td>1643</td> </tr> <tr> <td>Examiner Name</td> <td>Anne Gussow</td> </tr> <tr> <td colspan="2" style="height: 20px;"></td> </tr> </table>		Application Number	10/509,009	Filing Date	May 3, 2005	First Named Inventor	Chiquet-Ehrismann et al.	Art Unit	1643	Examiner Name	Anne Gussow		
Application Number	10/509,009																
Filing Date	May 3, 2005																
First Named Inventor	Chiquet-Ehrismann et al.																
Art Unit	1643																
Examiner Name	Anne Gussow																
Sheet	1	of	1	Attorney Docket No: FM-05-US													

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		REARDON, DAVID A. et al., Phase II Trial of Murine ¹³¹I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas; Journal of Clinical Oncology, Vol 20; No 5; pp 1389-1397; March 1, 2002.		

EXAMINER

DATE CONSIDERED